Ann: First-in-human study update - First patient enrolled, page-460

I doubt a positive announcement about phase 1 recruitment numbers will result in the market forgiving all of bobs errors.

there is still a long path to travel; pivotal studies, fda applications, commercial partnerships, machine manufacturing, commercial scale nanoparticle manufacturing, more capital raises etc.

look at the share price vs the known safety and efficacy information. the market has no faith in Bob. And Ibx is only just embarking on its approval/ commercialisation path.

Ibx needs a more seasoned leader. And the board needs to separate the chairman and ceo roles. The share price is telling us that. Zero confidence in this guy.